Literature DB >> 24526692

Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension.

Sherin Alias1, Bassam Redwan2, Adelheid Panzenboeck1, Max P Winter1, Uwe Schubert3, Robert Voswinckel4, Maria K Frey1, Johannes Jakowitsch1, Arman Alimohammadi1, Lukas Hobohm1, Andreas Mangold1, Helga Bergmeister5, Maria Sibilia6, Erwin F Wagner7, Eckhard Mayer8, Walter Klepetko9, Thomas J Hoelzenbein10, Klaus T Preissner3, Irene M Lang1.   

Abstract

OBJECTIVE: Restoration of patency is a natural target of vascular remodeling after venous thrombosis that involves vascular endothelial cells and smooth muscle cells, as well as leukocytes. Acute pulmonary emboli usually resolve <6 months. However, in some instances, thrombi transform into fibrous vascular obstructions, resulting in occlusion of the deep veins, or in chronic thromboembolic pulmonary hypertension (CTEPH). We proposed that dysregulated thrombus angiogenesis may contribute to thrombus persistence. APPROACH AND
RESULTS: Mice with an endothelial cell-specific conditional deletion of vascular endothelial growth factor receptor 2/kinase insert domain protein receptor were used in a model of stagnant flow venous thrombosis closely resembling human deep vein thrombosis. Biochemical and functional analyses were performed on pulmonary endarterectomy specimens from patients with CTEPH, a human model of nonresolving venous thromboembolism. Endothelial cell-specific deletion of kinase insert domain protein receptor and subsequent ablation of thrombus vascularization delayed thrombus resolution. In accordance with these findings, organized human CTEPH thrombi were largely devoid of vascular structures. Several vessel-specific genes, such as kinase insert domain protein receptor, vascular endothelial cadherin, and podoplanin, were expressed at lower levels in white CTEPH thrombi than in organizing deep vein thrombi and organizing thrombi from aortic aneurysms. In addition, red CTEPH thrombi attenuated the angiogenic response induced by vascular endothelial growth factor.
CONCLUSIONS: In the present work, we propose a mechanism of thrombus nonresolution demonstrating that endothelial cell-specific deletion of kinase insert domain protein receptor abates thrombus vessel formation, misguiding thrombus resolution. Medical conditions associated with the development of CTEPH may be compromising early thrombus angiogenesis.

Entities:  

Keywords:  endothelium; thrombosis; vascular endothelial growth factor receptor-2

Mesh:

Substances:

Year:  2014        PMID: 24526692      PMCID: PMC4728746          DOI: 10.1161/ATVBAHA.113.302991

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

1.  Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo.

Authors:  Y Y Kisanuki; R E Hammer; J Miyazaki ; S C Williams; J A Richardson; M Yanagisawa
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

2.  Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension.

Authors:  Amy L Firth; Weijuan Yao; Aiko Ogawa; Michael M Madani; Grace Y Lin; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2010-02-24       Impact factor: 4.249

3.  Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension.

Authors:  R Friedman; J G Mears; R J Barst
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

4.  Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.

Authors:  Vikram Sood; Catherine E Luke; K Barry Deatrick; Joseph Baldwin; Erin M Miller; Megan Elfline; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

5.  Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution.

Authors:  B Modarai; J Humphries; K G Burnand; J A Gossage; M Waltham; A Wadoodi; G S Kanaganayagam; A Afuwape; E Paleolog; A Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

6.  Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.

Authors:  I M Lang; J J Marsh; M A Olman; K M Moser; D J Loskutoff; R R Schleef
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

7.  Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension.

Authors:  Weijuan Yao; Amy L Firth; Richard S Sacks; Aiko Ogawa; William R Auger; Peter F Fedullo; Michael M Madani; Grace Y Lin; Naohide Sakakibara; Patricia A Thistlethwaite; Stuart W Jamieson; Lewis J Rubin; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-03-13       Impact factor: 5.464

8.  High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension.

Authors:  Timothy A Morris; James J Marsh; Peter G Chiles; Marisa M Magaña; Ni-Cheng Liang; Xavier Soler; Daniel J Desantis; Debby Ngo; Virgil L Woods
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

9.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension.

Authors:  Rozenn Quarck; Tim Nawrot; Bart Meyns; Marion Delcroix
Journal:  J Am Coll Cardiol       Date:  2009-04-07       Impact factor: 24.094

10.  Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.

Authors:  Joanna Chorostowska-Wynimko; Rafal Swiercz; Ewa Skrzypczak-Jankun; Steven H Selman; Jerzy Jankun
Journal:  Oncol Rep       Date:  2004-12       Impact factor: 3.906

View more
  24 in total

1.  AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis.

Authors:  Wanmu Xie; Lin Zhang; Wei Luo; Zhenguo Zhai; Chen Wang; Ying H Shen
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

2.  Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic pulmonary hypertension.

Authors:  F N Rahaghi; J C Ross; M Agarwal; G González; C E Come; A A Diaz; G Vegas-Sánchez-Ferrero; A Hunsaker; R San José Estépar; A B Waxman; G R Washko
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.

Authors:  Evandro M Neto-Neves; Mary B Brown; Maria V Zaretskaia; Samin Rezania; Adam G Goodwill; Brian P McCarthy; Scott A Persohn; Paul R Territo; Jeffrey A Kline
Journal:  Am J Pathol       Date:  2017-02-07       Impact factor: 4.307

Review 4.  Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Krittika Teerapuncharoen; Remzi Bag
Journal:  Lung       Date:  2022-05-29       Impact factor: 2.584

5.  Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Magdalena L Bochenek; Christiane Leidinger; Nico S Rosinus; Rajinikanth Gogiraju; Stefan Guth; Lukas Hobohm; Kerstin Jurk; Eckhard Mayer; Thomas Münzel; Mareike Lankeit; Markus Bosmann; Stavros Konstantinides; Katrin Schäfer
Journal:  Circ Res       Date:  2019-11-21       Impact factor: 17.367

Review 6.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

Review 7.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

Review 8.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

Review 9.  Assessment of Venous Thrombosis in Animal Models.

Authors:  Steven P Grover; Colin E Evans; Ashish S Patel; Bijan Modarai; Prakash Saha; Alberto Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

Review 10.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.